Skip to main content
ABCL
NASDAQ Life Sciences

AbCellera Reports Strong Q1 Results & Positive Phase 1 Data for ABCL635, Advancing to Phase 2

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$5.579
Mkt Cap
$1.592B
52W Low
$1.94
52W High
$6.515
52W Position info
188% above low
Off High info
14% below high
Rel. Volume info
2.5× avg
Market data snapshot near publication time

ABCL has more than doubled off its 52-week low of $1.94 on elevated volume (2.5× avg).

Summary

AbCellera Biologics reported improved Q1 2026 financial results and positive interim Phase 1 data for its lead antibody candidate, ABCL635, which is now advancing to Phase 2.


Key Events · Product Development and Regulatory · ABCL

  • Positive ABCL635 Phase 1 Data

    Interim results for ABCL635, a potential first-in-class antibody for vasomotor symptoms, showed a favorable tolerability profile, no liver toxicity, and strong suppression of target engagement biomarkers.

  • Advancement to Phase 2

    Based on the positive Phase 1 data, ABCL635 has advanced into a Phase 2 study, with topline results anticipated in Q3 2026.

  • Improved Q1 2026 Financials

    The company reported increased total revenue of $8.3 million (up from $4.2 million in Q1 2025) and a reduced net loss of $43.2 million (down from $45.6 million in Q1 2025).

  • Strong Liquidity Position

    AbCellera ended Q1 2026 with approximately $655 million in total available liquidity, providing a substantial runway for its clinical development programs.


Analysis · ABCL · Life Sciences

This filing is highly important for AbCellera as it provides significant de-risking for its lead clinical asset, ABCL635. The positive Phase 1 data, demonstrating a favorable safety profile and strong target engagement, supports the program's progression into Phase 2, a critical milestone for a biotech. This clinical advancement, combined with improved Q1 financial results and a robust liquidity position of $655 million, strengthens the company's ability to fund its pipeline and execute its development strategy. Investors will now focus on the upcoming Phase 2 topline readout for ABCL635 in Q3 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ABCL was trading at $5.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $1.94 to $6.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ABCL - Latest Insights

ABCL
Nov 09, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.54
Real-time Price: $10.30 info
Change: -$2.24 (-18%) info
Market Cap: $3.42B info
ABCL
Nov 09, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $12.90
Real-time Price: $10.30 info
Change: -$2.60 (-20%) info
Market Cap: $3.42B info
ABCL
Aug 13, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.97
Real-time Price: $10.30 info
Change: -$0.670 (-6%) info
Market Cap: $3.42B info
ABCL
Aug 13, 2026, 12:05 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $10.32
Real-time Price: $10.30 info
Change: -$0.020 (-0.19%) info
Market Cap: $3.42B info
ABCL
Aug 11, 2026, 4:59 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $9.32
Real-time Price: $10.30 info
Change: +$0.980 (+11%) info
Market Cap: $3.42B info